PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Some net income increase while AGEN is negative at -220.35%. John Neff would see a short-term edge over the struggling competitor.
-1.40%
Negative yoy D&A while AGEN is 31.47%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Both cut yoy SBC, with AGEN at -23.98%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
5.95%
Less working capital growth vs. AGEN's 69.39%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Both negative yoy AP, with AGEN at -113.58%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
823.30%
Growth well above AGEN's 81.89%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
59.87%
Lower 'other non-cash' growth vs. AGEN's 7672.98%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-19.06%
Both yoy CFO lines are negative, with AGEN at -29.63%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
96.37%
Some CapEx rise while AGEN is negative at -412.69%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
Both yoy lines negative, with AGEN at -452.36%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
92.69%
We repay more while AGEN is negative at -0.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-1494.87%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.